MetLife Investment Management’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $285K | Hold |
10,527
| – | – | ﹤0.01% | 2034 |
|
|
2025
Q4 | $451K | Hold |
10,527
| – | – | ﹤0.01% | 1841 |
|
|
2025
Q3 | $298K | Sell |
10,527
-1,467
| -12% | -$43.9K | ﹤0.01% | 2091 |
|
|
2025
Q2 | $225K | Hold |
11,994
| – | – | ﹤0.01% | 2129 |
|
|
2025
Q1 | $216K | Sell |
11,994
-264
| -2% | -$5.36K | ﹤0.01% | 2158 |
|
|
2024
Q4 | $206K | Buy |
12,258
+2,014
| +20% | +$38.6K | ﹤0.01% | 2288 |
|
|
2024
Q3 | $166K | Sell |
10,244
-1
| -0% | -$12 | ﹤0.01% | 2380 |
|
|
2024
Q2 | $84.2K | Buy |
10,245
+3,003
| +41% | +$31.4K | ﹤0.01% | 2673 |
|
|
2024
Q1 | $107K | Sell |
7,242
-2,030
| -22% | -$27.4K | ﹤0.01% | 2501 |
|
|
2023
Q4 | $134K | Hold |
9,272
| – | – | ﹤0.01% | 2459 |
|
|
2023
Q3 | $100K | Hold |
9,272
| – | – | ﹤0.01% | 2574 |
|
|
2023
Q2 | $120K | Hold |
9,272
| – | – | ﹤0.01% | 2578 |
|
|
2023
Q1 | $122K | Buy |
9,272
+2,791
| +43% | +$44.3K | ﹤0.01% | 2468 |
|
|
2022
Q4 | $97.2K | Sell |
6,481
-3,055
| -32% | -$28K | ﹤0.01% | 2602 |
|
|
2022
Q3 | $113K | Buy |
9,536
+8,764
| +1,135% | +$119K | ﹤0.01% | 2626 |
|
|
2022
Q2 | $8.72K | Sell |
772
-7,799
| -91% | -$157K | ﹤0.01% | 2852 |
|
|
2022
Q1 | $256K | Buy |
8,571
+5,613
| +190% | +$152K | ﹤0.01% | 2199 |
|
|
2021
Q4 | $78.4K | Sell |
2,958
-3,199
| -52% | -$96.5K | ﹤0.01% | 2454 |
|
|
2021
Q3 | $223K | Buy |
6,157
+1,987
| +48% | +$78.2K | ﹤0.01% | 2018 |
|
|
2021
Q2 | $181K | Sell |
4,170
-2,763
| -40% | -$104K | ﹤0.01% | 2228 |
|
|
2021
Q1 | $237K | Buy |
6,933
+2,155
| +45% | +$85.3K | ﹤0.01% | 1964 |
|
|
2020
Q4 | $167K | Buy |
4,778
+69
| +1% | +$2K | ﹤0.01% | 2078 |
|
|
2020
Q3 | $113K | Sell |
4,709
-3,390
| -42% | -$83.2K | ﹤0.01% | 2163 |
|
|
2020
Q2 | $148K | Buy |
8,099
+4,124
| +104% | +$74.2K | ﹤0.01% | 2062 |
|
|
2020
Q1 | $62K | Sell |
3,975
-4,359
| -52% | -$92.8K | ﹤0.01% | 2220 |
|
|
2019
Q4 | $178K | Buy |
8,334
+6,948
| +501% | +$143K | ﹤0.01% | 2040 |
|
|
2019
Q3 | $25.9K | Sell |
1,386
-9,335
| -87% | -$193K | ﹤0.01% | 2326 |
|
|
2019
Q2 | $280K | Buy |
10,721
+3,906
| +57% | +$88.2K | ﹤0.01% | 1832 |
|
|
2019
Q1 | $175K | Hold |
6,815
| – | – | ﹤0.01% | 2042 |
|
|
2018
Q4 | $157K | Hold |
6,815
| – | – | ﹤0.01% | 2044 |
|
|
2018
Q3 | $219K | Sell |
6,815
-3,321
| -33% | -$99.7K | ﹤0.01% | 2031 |
|
|
2018
Q2 | $287K | Buy |
10,136
+3,509
| +53% | +$125K | ﹤0.01% | 1736 |
|
|
2018
Q1 | $235K | Hold |
6,627
| – | – | ﹤0.01% | 1803 |
|
|
2017
Q4 | $257K | Buy |
+6,627
| New | +$252K | ﹤0.01% | 1793 |
|
Other funds holding RIGL
AC
VCM
MetLife Investment Management's RIGL Position: Q1 2026 in Review
MetLife Investment Management held its Rigel Pharmaceuticals (RIGL) position steady in Q1 2026 at 10,527 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #2034.
MetLife Investment Management first reported a position in RIGL in Q4 2017 and has held it in 34 quarters since. The position peaked at $451K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- MetLife Investment Management held 10,527 shares of Rigel Pharmaceuticals worth $285K as of Q1 2026.
- MetLife Investment Management left its Rigel Pharmaceuticals share count unchanged in Q1 2026.
- Rigel Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2034 holding.
- MetLife Investment Management first reported a position in Rigel Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Rigel Pharmaceuticals position peaked at $451K in Q4 2025.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.